Fogarty E - Search Results

1

Pharmaceutical regulation in 15 European countries review.

Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, Jommi C, Kaitelidou D, Kawalec P, Keskimaki I, Kroneman M, Lopez Bastida J, Pita Barros P, Ramsberg J, Schneider P, Spillane S, Vogler S, Vuorenkoski L, Wallach Kildemoes H, Wouters O, Busse R. Panteli D, et al. Among authors: fogarty e. Health Syst Transit. 2016 Oct;18(5):1-122. Health Syst Transit. 2016. PMID: 27929376 Free article. Review.

2

The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?

Gold R, Toumi M, Meesen B, Fogarty E. Gold R, et al. Among authors: fogarty e. Mult Scler. 2016 Aug;22(2 Suppl):60-70. doi: 10.1177/1352458516650743. Mult Scler. 2016. PMID: 27465616 Review.

3

Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5D.

Fogarty E, Walsh C, Adams R, McGuigan C, Barry M, Tubridy N. Fogarty E, et al. Mult Scler. 2013 Aug;19(9):1190-6. doi: 10.1177/1352458512474860. Epub 2013 Feb 11. Mult Scler. 2013. PMID: 23401128

4

Economic costs associated with an MS relapse.

O'Connell K, Kelly SB, Fogarty E, Duggan M, Buckley L, Hutchinson M, McGuigan C, Tubridy N. O'Connell K, et al. Among authors: fogarty e. Mult Scler Relat Disord. 2014 Nov;3(6):678-83. doi: 10.1016/j.msard.2014.09.002. Epub 2014 Sep 16. Mult Scler Relat Disord. 2014. PMID: 25891546

5

Health Technology Assessment International 7th Annual Meeting: Dublin, Ireland, 6–9 June 2010.

Fogarty E, Tilson L, Ryan M, Barry M. Fogarty E, et al. Expert Rev Pharmacoecon Outcomes Res. 2010 Oct;10(5):501-3. doi: 10.1586/erp.10.59. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 20950064

6

The Utility of a Rapid Review Evaluation Process to a National HTA Agency.

Varley Á, Tilson L, Fogarty E, McCullagh L, Barry M. Varley Á, et al. Among authors: fogarty e. Pharmacoeconomics. 2022 Feb;40(2):203-214. doi: 10.1007/s40273-021-01093-8. Epub 2021 Oct 12. Pharmacoeconomics. 2022. PMID: 34635994 Free PMC article. Review.

7

Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis.

Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Fogarty E, et al. Mult Scler Relat Disord. 2016 Sep;9:23-30. doi: 10.1016/j.msard.2016.06.001. Epub 2016 Jun 8. Mult Scler Relat Disord. 2016. PMID: 27645339 Review.

8

Direct and indirect economic consequences of multiple sclerosis in Ireland.

Fogarty E, Walsh C, McGuigan C, Tubridy N, Barry M. Fogarty E, et al. Appl Health Econ Health Policy. 2014 Dec;12(6):635-45. doi: 10.1007/s40258-014-0128-3. Appl Health Econ Health Policy. 2014. PMID: 25227118

9

The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.

O'Brien C, Fogarty E, Walsh C, Dempsey O, Barry M, Kennedy MJ, McCullagh L. O'Brien C, et al. Among authors: fogarty e. Eur J Cancer Care (Engl). 2015;24(1):125-32. doi: 10.1111/ecc.12182. Epub 2014 Jan 29. Eur J Cancer Care (Engl). 2015. PMID: 24472035

10

Predicted Versus Actual Budget Impact of High-Cost Drugs In Ireland.

Fogarty E, Barry M. Fogarty E, et al. Value Health. 2014 Nov;17(7):A426-7. doi: 10.1016/j.jval.2014.08.1069. Epub 2014 Oct 26. Value Health. 2014. PMID: 27201099 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

158 results

Search Page